Navigation Links
ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
Date:9/4/2007

production technology from one company to another, or from one country to another, can be a complex process. This milestone proves the commitment from both sides to use their substantial scientific skills to supply THR-100, a novel recombinant therapeutic, to the developing world. With this successful collaboration, we look forward to moving this unique thrombolytic agent quickly into the clinic and toward commercialization."

Commenting on the technology transfer, Dr. Krishna M. Ella, Chairman and Managing Director of Bharat Biotech, said, "Successful transfer of technology from ThromboGenics to Bharat Biotech is a significant milestone in the development of THR-100 as a novel thrombolytic agent. Bharat Biotech has significant expertise in executing technology transfer processes from U.S. and EU companies. We are highly excited about further clinical development of THR-100 and its commercialization."

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics also has one program, TB-402 (Anti-Factor VIII), in Phase I clinical trials, and three other drug candidates in preclinical development with preclinical proof-of-principle demonstrated. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland, and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... 2014 Women in the West ... an additional family planning option. Sayana® Press has ... all levels of the health system and in ... widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the ... the first of four African countries expected to ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., ... the relaunch of his highly informative blog, now named Stem ... What are Stem Cells ?” Dr. Harman’s purpose for ... the basics of stem cell therapy so that pet owners ... treatment when considering regenerative medicine. , A veterinarian by trade, ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... today the establishment of a collaboration with Ono ... and development of small molecule modulators of an ... terms of the agreement, Receptos will use its ... crystal structures of the discovery target and drive ...
... , Inc ... called Zybodies™, announced today that it has promoted ... and appointed Daniel L. Menichella as Chief Business ... in September 2009, Zyngenia has made tremendous progress in both developing ...
... NEW YORK, Dec. 12, 2011  Fox Insurance Company, a ... NY, announces a judgment in the arbitration between the ... excess of $3.3 million, following a suit against ProCare ... contract.  Nathan M. Barotz, chairman of ...
Cached Biology Technology:Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research 2Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research 3Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 2Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 3Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager 2
(Date:7/11/2014)... The Chinese University of Hong Kong, BGI and other ... to salt tolerance, with implication for improving this important ... online in Nature Communications provides an effective ... , Soybean is an important crop for the world. ... less genetic diversities than their wild counterparts. Among the ...
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... kidney injury related to the use of hydroxyethyl starch ... molecules, according to a report in Anesthesia & ... Society (IARS). , The "total mass of HES molecules" ... renal proximal tubule cells (PTCs), concludes the laboratory study ... Wrzburg, Austria. Other factorssuch as differences in the ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... day of competition in London, a team of four ... emerged as the winners of this year,s Biotechnology Young ... Biotechnology Young Entrepreneurs Scheme (YES) competition are Ben Owens, ... University of Oxford. The team pitched their ...
... -- The International Center for Tropical Agriculture (CIAT) ... a collaborative agreement to sequence 5,000 cassava genotypes, ... wild species of the crop. Cassava is the ... developing countries (after maize, wheat and rice.) Results ...
... exploded in Yambuku, a remote village in Zaire, (now the ... Ebola had emerged, soon earning a grim distinction as one ... up to 90 percent of its victims, and producing a ... Charles Arntzen, a researcher at the Biodesign Institute at Arizona ...
Cached Biology News:Winning early-career researchers excel in entrepreneurship 2Winning early-career researchers excel in entrepreneurship 3BGI and CIAT announce collaboration for large-scale genome sequencing of cassava 2BGI and CIAT announce collaboration for large-scale genome sequencing of cassava 3Defensive measures: Toward a vaccine for Ebola 2Defensive measures: Toward a vaccine for Ebola 3Defensive measures: Toward a vaccine for Ebola 4Defensive measures: Toward a vaccine for Ebola 5
Mol wt: average mol wt16,951.27 Da by calculation...
... is the only PCR system that ensures ... time. It provides accuracy, consistency, and dependability ... the property of the DNA templates. This ... a unique blend of thermostable enzymes that ...
... C2C12 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... set-up Easy to assemble ... tubes, strips or Nunc 96 Well Amplifications ... tray can be fitted directly into the thermal cycler ... thermal cycler formats of major manufacturers Alphanumerically ...
Biology Products: